chr4-109729648-G-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_030821.5(PLA2G12A):āc.162C>Gā(p.Asp54Glu) variant causes a missense change. The variant allele was found at a frequency of 0.0000726 in 1,611,866 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000079 ( 0 hom., cov: 32)
Exomes š: 0.000072 ( 0 hom. )
Consequence
PLA2G12A
NM_030821.5 missense
NM_030821.5 missense
Scores
1
6
12
Clinical Significance
Conservation
PhyloP100: 5.51
Genes affected
PLA2G12A (HGNC:18554): (phospholipase A2 group XIIA) Secreted phospholipase A2 (sPLA2) enzymes liberate arachidonic acid from phospholipids for production of eicosanoids and exert a variety of physiologic and pathologic effects. Group XII sPLA2s, such as PLA2G12A, have relatively low specific activity and are structurally and functionally distinct from other sPLA2s (Gelb et al., 2000 [PubMed 11031251]).[supplied by OMIM, Mar 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PLA2G12A | NM_030821.5 | c.162C>G | p.Asp54Glu | missense_variant | 1/4 | ENST00000243501.10 | NP_110448.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PLA2G12A | ENST00000243501.10 | c.162C>G | p.Asp54Glu | missense_variant | 1/4 | 1 | NM_030821.5 | ENSP00000243501.5 | ||
PLA2G12A | ENST00000502283.1 | c.162C>G | p.Asp54Glu | missense_variant | 1/4 | 1 | ENSP00000425274.1 | |||
ENSG00000285330 | ENST00000645635.1 | c.1535-10889C>G | intron_variant | ENSP00000493607.1 | ||||||
PLA2G12A | ENST00000507961.1 | n.162C>G | non_coding_transcript_exon_variant | 1/3 | 2 | ENSP00000424021.1 |
Frequencies
GnomAD3 genomes AF: 0.0000788 AC: 12AN: 152218Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
12
AN:
152218
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000320 AC: 8AN: 249836Hom.: 0 AF XY: 0.0000443 AC XY: 6AN XY: 135356
GnomAD3 exomes
AF:
AC:
8
AN:
249836
Hom.:
AF XY:
AC XY:
6
AN XY:
135356
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000719 AC: 105AN: 1459648Hom.: 0 Cov.: 31 AF XY: 0.0000799 AC XY: 58AN XY: 726132
GnomAD4 exome
AF:
AC:
105
AN:
1459648
Hom.:
Cov.:
31
AF XY:
AC XY:
58
AN XY:
726132
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000788 AC: 12AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74358
GnomAD4 genome
AF:
AC:
12
AN:
152218
Hom.:
Cov.:
32
AF XY:
AC XY:
6
AN XY:
74358
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
4
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 13, 2024 | The c.162C>G (p.D54E) alteration is located in exon 1 (coding exon 1) of the PLA2G12A gene. This alteration results from a C to G substitution at nucleotide position 162, causing the aspartic acid (D) at amino acid position 54 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T
M_CAP
Benign
T
MetaRNN
Uncertain
D;D
MetaSVM
Benign
T
MutationAssessor
Benign
L;.
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Benign
T;T
Sift4G
Benign
T;T
Polyphen
D;.
Vest4
MutPred
Gain of solvent accessibility (P = 0.1751);Gain of solvent accessibility (P = 0.1751);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at